2017
DOI: 10.1080/2331205x.2017.1412903
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of recalcitrant actinic keratosis (AK) of the scalp by cold atmospheric plasma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 24 publications
0
9
0
Order By: Relevance
“…A recent innovation in plasma oncology is the treatment of carcinoma in situ , e.g., actinic keratosis [6769]. These dry, crusty, superficial lesions of the skin have a very high prevalence, and a significant percentage of lesions can develop into invasive squamous cell carcinoma over time.…”
Section: Plasma-derived Ros In Medical Therapymentioning
confidence: 99%
“…A recent innovation in plasma oncology is the treatment of carcinoma in situ , e.g., actinic keratosis [6769]. These dry, crusty, superficial lesions of the skin have a very high prevalence, and a significant percentage of lesions can develop into invasive squamous cell carcinoma over time.…”
Section: Plasma-derived Ros In Medical Therapymentioning
confidence: 99%
“…A case report from Daeschlein and colleagues showed promising results of CAP in a patient with recalcitrant actinic keratosis of the scalp [76]. No actinic lesion relapse has been observed until at least 26 months after a single treatment with CAP, and furthermore, scar formation had been proven.…”
Section: Actinic Keratosismentioning
confidence: 99%
“…Regarding plasma medicine, several devices have so far received accreditation as medical device class IIa in Europe [130]. However, plasma application in cancer patients has been mostly performed within exploratory studies [138,[171][172][173][174][175], and a guideline-based indication of plasma devices in cancer treatment is not given as of now. State-of-the-art NP synthesis methods, which can address some challenges of traditional bulk techniques, have not been considered in most clinical trials.…”
Section: Challenges To Achieving Clinical Success and Futurementioning
confidence: 99%